Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CHILDREN S IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus CHILDREN S IBUPROFEN.
ALEVE-D SINUS & COLD vs CHILDREN'S IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Category C
Category D/X
NSAID/Decongestant Combination
NSAID